Adénocarcinome ductal pancréatique (PDAC) · ligne 1 · Aucune
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.
| Ligne thérapeutique | 1 |
|---|---|
| Voie | standard |
| Régime lié | None |
| ID | IND-PDAC-LAPC-CHEMORADIATION |
|---|---|
| Type | Indication |
| État | reviewed 2026-05-08 | pending_clinical_signoff | actionability review required |
| Maladies | DIS-PDAC |
| Sources | SRC-ESMO-PANCREATIC-2024 SRC-NCCN-PANCREATIC-2025 |
Notes
§17 phased indication — 2-phase induction → consolidation CRT for locally advanced unresectable PDAC (LAPC). Phase 1 induction REG-FOLFIRINOX × 6 cycles (mFOLFIRINOX equivalent-fidelity alternative for marginal-fit; not modeled as a separate phase entry here — render layer surfaces both via REG-FOLFIRINOX/REG-MFOLFIRINOX comment). Phase 2 definitive consolidation chemoradiation via RC-LAPC-CHEMORADIATION-PDAC (50.4 Gy / 28 fx, intent: definitive, concurrent_chemo_regimen explicitly null pending REG-CAPECITABINE-CRT-CONCURRENT authoring — same gap as C4 rectal LCCRT, to be backfilled in dedicated chunk; concurrent capecitabine 825 mg/m^2 PO BID on RT days fully captured in RC schedule + notes). LAP07 (Hammel JAMA 2016) and CONKO-007 (Fietkau ASCO 2022) source stubs deferred — neither pivotal-trial source exists in the KB yet; primary citations route through SRC-NCCN-PANCREATIC-2025 and SRC-ESMO-PANCREATIC-2024 which themselves cite both trials and carry the consensus-recommendation evidence chain. Future chunk should author the LAP07-Hammel-2016 and CONKO-007-Fietkau-2022 source stubs and back-fill direct citations into rationale and RC notes. Evidence-level moderate + strength con...
Utilisé par
Algorithmes
ALGO-PDAC-LAPC- ALGO-PDAC-LAPC